AstraZeneca and its research and development arm MedImmune have reported negative top-line results from the TERRANOVA trial after it failed to meet its primary objective.

However, the safety and tolerability results were similar to those observed in previous trials of Fasenra.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

TERRANOVA is AstraZeneca’s second of the two pivotal Phase III trials designed to evaluate Fasenra (benralizumab) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

The randomised, double-blinded, 56-week placebo-controlled, multicentre trial’s primary objective included a statistically significant reduction of exacerbations in COPD patients.

“These results are disappointing because uncontrolled COPD patients already on dual or triple inhaled therapy need new treatment options.”

The trial evaluated the safety and efficacy of Fasenra as an add-on to dual or triple inhaled therapy against placebo in patients with moderate to very severe COPD with a history of exacerbations across a range of baseline blood eosinophils.

Findings of the TERRANOVA trial follow negative results from the company’s first pivotal Phase III trial of Fasenra for COPD, GALATHEA. The results were reported earlier this month.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

AstraZeneca Global Medicines Development executive vice-president and chief medical officer Dr Sean Bohen said: “These results are disappointing because uncontrolled COPD patients already on dual or triple inhaled therapy need new treatment options.

“We will now analyse the complete data sets from the GALATHEA and TERRANOVA trials to further understand these results.”

The company currently has no plan to submit a regulatory application for Fasenra, which is a monoclonal antibody that hires natural killer cells to induce rapid and near-complete depletion of eosinophils, a type of white blood cell that is a normal part of the body’s immune system.